Skip to content

Efficacy and safety of vonoprazan and minocycline dual therapy in treating Helicobacter pylori infection in patients with penicillin allergy

Efficacy and safety of vonoprazan and minocycline dual therapy in treating Helicobacter pylori infection in patients with penicillin allergy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107510
Enrollment
Unknown
Registered
2025-08-13
Start date
2025-08-15
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

LBMM quadruple therapy group:LBMM quadruple therapy
VM dual therapy group:VM dual therapy

Sponsors

Bejing Tongren Hospital, Capital Medical Uniersity
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 70 years, no gender restriction; 2. Positive for Helicobacter pylori (indicated by a positive urease breath test and histopathologic examination); 3. Allergic to penicillin (including those with a positive penicillin skin test or patients who have experienced an allergic reaction after using penicillin);

Exclusion criteria

Exclusion criteria: 1.Patients who have previously received treatment for Helicobacter pylori; 2.Patients allergic to any investigational drug; 3.Patients who have used antibiotics or bismuth within 4 weeks prior to enrollment, or acid suppressants within 2 weeks prior to enrollment; 4.Patients with significant organ dysfunction such as cardiac, respiratory, renal and nervous system diseases and malignant tumors, etc.; 5.Pregnant or lactating women; 6.Other situations that investigators believe unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Eradication rates;

Secondary

MeasureTime frame
Adverse event;Compliance;

Countries

China

Contacts

Public ContactJianhong Chen

Bejing Tongren Hospital, Capital Medical Uniersity

chenjianhong829@126.com+86 10 58266053

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026